比较胸外科手术中肋间神经阻滞时机疗效的随机对照试验:一项随机临床试验的研究方案
这是一项单盲、单中心随机对照试验方案,计划于2024年9月29日至2026年6月30日在筑波大学医院胸外科开展,纳入16至79岁、ASA-PS分级1至3级、经电视辅助胸腔镜手术行肺楔形切除且不使用操作孔的患者,比较术前与关胸前实施肋间神经阻滞的术后镇痛效果,主要结局为返回病房后4小时活动时数值评定量表疼痛评分。
要点
- 研究比较术前与关胸前实施肋间神经阻滞对术后镇痛效果的影响。
- 主要结局为返回病房后4小时活动时数值评定量表疼痛评分。
- 次要结局包括追加镇痛药、术中指标、急性与慢性疼痛及生活质量。
核心结论
- 研究旨在检验术前实施肋间神经阻滞较关胸前实施提供更优术后镇痛效果的假设,并观察围术期结局以判断时机是否影响急慢性术后疼痛或术中患者管理。
研究设计与样本
- 单盲、单中心、随机对照试验,计划于2024年9月29日至2026年6月30日在筑波大学医院胸外科开展。
- 纳入16至79岁、ASA-PS分级1至3级、经电视辅助胸腔镜手术行肺楔形切除且不使用操作孔的患者,随机接受术前或关胸前肋间神经阻滞,仅对患者设盲。
主要发现
- 主要结局为返回病房后4小时活动时数值评定量表疼痛评分。
- 次要结局包括返回病房4小时内追加镇痛药使用、术中测量指标(瑞芬太尼用量、手术结束至拔管时间、拔管后寒战或恶心发生、止吐药使用及最高血压/心率)、住院期间急性疼痛、术后镇痛药使用及术前与术后3个月时点EQ-5D和SF-36生活质量评分。
- 术后3个月慢性疼痛亦通过数值评定量表判定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Even minimally invasive thoracic surgeries carry a postoperative cost in pain. While regional anesthesia may alleviate this anticipated pain, especially intercostal nerve blocks (ICNB), the timing of block administration for optimal effect (at the beginning of surgery vs. before wound closure) remains controversial. Here, we plan (1) to test the hypothesis that performing ICNB at the beginning of surgery provides superior postoperative analgesic effects compared to before wound closure and (2) to observe perioperative outcomes to determine whether the timing affects acute and chronic postoperative pain, or intraoperative patient management. METHODS: This single-blinded, single-center, randomized, controlled trial will be conducted at the Department of Thoracic Surgery, University of Tsukuba Hospital from Sep 29, 2024, to June 30, 2026. Patients 16-79 years old within the regular population of patients undergoing lung wedge resection via video-assisted thoracoscopic surgery (VATS) without a utility window approach and who are ASA-PS classes 1-3 will be enrolled to receive ICNB either pre-operatively or before wound closure. Groups will be single-blinded (patient only) at random, and the primary outcome will be assessment by Numerical Rating Scale (NRS) pain scores during movement, measured 4 h after returning to the ward. Secondary outcomes will be (1) any additional analgesic use within the 4-h return window, (2) intraoperative measurements (including amounts of remifentanil used, time from surgery completion to extubation, occurrence of shivering or nausea after extubation, use of antiemetics, and maximum blood pressure/heart rate), (3) acute pain during hospitalization (using routinely administered NRS), (4) postoperative analgesic use, and (5) quality of life (QOL) scores on EQ-5D and SF-36 questionnaires at preoperative and 3-month postoperative timepoints. Chronic pain at 3 months post-surgery will also be determined by NRS. DISCUSSION: A complete evaluation of ICNB efficacy as a preemptive analgesic approach will contribute to the development of improved perioperative pain management techniques. A reduction in the duration of surgery-related symptoms and an improvement in postoperative QOL will be the result. TRIAL REGISTRATION: Japan Registry of Clinical Trials: identifier jRCT1031240358. Registered on 29 Sep 2024. https://jrct.niph.go.jp/latest-detail/jRCT1031240358 .
引用
- Sekine Y, Ichimura H, Ueda S, et al. Randomized, controlled trial comparing the efficacy of intercostal nerve block in thoracoscopic surgery by timing: study protocol for a randomized clinical trial. Trials. 2025. PMID: 40849480. doi:10.1186/s13063-025-09059-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。